We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
PHO.OL

Price
51.90
Stock movement up
+0.80 (1.57%)
Company name
Photocure
Exchange
(OL
,
Currency
NOK
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
1.41B
Ent value
1.35B
Price/Sales
2.74
Price/Book
2.82
Div yield
1.02%
Div growth
19.62%
Growth years
1
FCF payout
-
Trailing P/E
109.55
Forward P/E
89.48
PEG
-
EPS growth
-
1 year return
-10.21%
3 year return
-24.06%
5 year return
-4.28%
10 year return
5.46%
Last updated: 2025-04-12

DIVIDENDS

Dividend yield - 5y

Dividend yield data
Dividend per share0.53
Dividend yield1.02%
Payout frequencyQuarterly
Maximum yield1.30%
Average yield0.95%
Minimum yield0.47%
Discount to avg yield6.59%
Upside potential7.06%
Yield as % of max yield78.71%

Yield distribution (inverse percentile) - 5y

Yield distribution data
Dividend yield1.02%
Current yield distribution30.94%
Yield at 100% (Min)0.47%
Yield at 90%0.80%
Yield at 80%0.87%
Yield at 50% (Median)0.97%
Yield at 20%1.05%
Yield at 10%1.10%
Yield at 0% (Max)1.30%

Dividend per share

Dividend per share data
Years of growth1 years
CCC status-
Dividend per share0.53
Payout frequencyQuarterly
Ex-div date19 Dec 2022
EPS (TTM)0.47
EPS (1y forward)0.58
EPS growth (5y)-
EPS growth (5y forward)-

Dividend growth

Please create a free account or log in to access this chart
Dividend growth data
PHO.OLS&P500
DGR MR237.26%-13.74%
DGR TTM106.31%6.60%
DGR 3 years14.30%5.24%
DGR 5 years19.62%5.40%
DGR 10 years-7.07%
DGR 15 years-6.12%
Time since last change announced851 days
EPS growth (5y)-
EPS growth (5y forward)-

Payout ratio

Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM--
Average--
Forward91.38%-

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E109.55
Price to OCF26.59
Price to FCF32.45
Price to EBITDA421.32
EV to EBITDA405.42

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales2.74
Price to Book2.82
EV to Sales2.64

FINANCIALS

Per share

Per share data
Current share count27.11M
EPS (TTM)0.47
FCF per share (TTM)1.60

Income statement

Income statement data
Revenue (TTM)513.58M
Gross profit (TTM)485.43M
Operating income (TTM)40.03M
Net income (TTM)12.84M
EPS (TTM)0.47
EPS (1y forward)0.58

Margins

Margins data
Gross margin (TTM)94.52%
Operating margin (TTM)7.79%
Profit margin (TTM)2.50%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash266.99M
Net receivables72.04M
Total current assets387.64M
Goodwill144.00M
Intangible assets116.57M
Property, plant and equipment23.54M
Total assets713.58M
Accounts payable16.21M
Short/Current long term debt0.00
Total current liabilities66.65M
Total liabilities213.92M
Shareholder's equity499.66M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)52.90M
Capital expenditures (TTM)9.56M
Free cash flow (TTM)43.35M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity2.57%
Return on Assets1.80%
Return on Invested Capital2.57%
Cash Return on Invested Capital8.68%

STOCK INFORMATION

Stock chart

Stock price data
Open50.60
Daily high52.20
Daily low50.40
Daily Volume16K
All-time high150.90
1y analyst estimate84.50
Beta0.99
EPS (TTM)0.47
Dividend per share0.53
Ex-div date19 Dec 2022
Next earnings date13 May 2025

Downside potential

Downside potential data
PHO.OLS&P500
Current price drop from All-time high-65.61%-12.89%
Highest price drop-86.82%-56.47%
Date of highest drop4 Nov 20149 Mar 2009
Avg drop from high-60.92%-11.07%
Avg time to new high430 days12 days
Max time to new high4968 days1805 days
COMPANY DETAILS
PHO.OL (Photocure) company logo
Marketcap
1.41B
Marketcap category
Small-cap
Description
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira, as well as strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Employees
102
Website
https://www.photocure.com
Investor relations
-
SEC filings
PHO.OL SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
Photocure appoints Jane Healy as Vice President and General Manager EMEA
Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA.
March 26, 2025
Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in Madrid, Spain, highlighting the benefits of Blu...
March 24, 2025
New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU ...
March 14, 2025
Photocure ASA: Results for the fourth quarter of 2024
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK 29.9 million). Photo...
February 19, 2025
News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared
Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces an update regarding its ongoing collaboration with Richard Wolf to develop a high-definition flexible blue light cystoscope for global c...
February 17, 2025
Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025
Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American ...
February 17, 2025
Photocure ASA: Results for the third quarter of 2024
Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and EBITDA of NOK 5.0 million (NOK 3.3 million) for th...
November 13, 2024
Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international multicenter Phase III clinical study data for its...
September 30, 2024
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part of the Clinigen group, in September, to initiate a Named...
September 27, 2024
Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that international multicenter Phase III clinical trial da...
September 17, 2024
Next page
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved